Checchi Capital Advisers LLC Continues to Hold Position in Ionis Pharmaceuticals, Inc. (IONS)
Checchi Capital Advisers LLC continued to hold its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the second quarter, Holdings Channel reports. The firm owned 17,823 shares of the company’s stock at the end of the second quarter. Checchi Capital Advisers LLC’s holdings in Ionis Pharmaceuticals were worth $907,000 as of its most recent filing with the SEC.
A number of other large investors also recently modified their holdings of the company. Teacher Retirement System of Texas increased its stake in shares of Ionis Pharmaceuticals by 0.4% in the second quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock worth $492,000 after buying an additional 43 shares in the last quarter. Public Employees Retirement Association of Colorado increased its stake in shares of Ionis Pharmaceuticals by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock worth $1,241,000 after buying an additional 65 shares in the last quarter. Utah Retirement Systems increased its stake in shares of Ionis Pharmaceuticals by 0.5% in the first quarter. Utah Retirement Systems now owns 22,000 shares of the company’s stock worth $884,000 after buying an additional 100 shares in the last quarter. Grandfield & Dodd LLC increased its stake in shares of Ionis Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 12,119 shares of the company’s stock worth $487,000 after buying an additional 135 shares in the last quarter. Finally, Raymond James Trust N.A. increased its stake in shares of Ionis Pharmaceuticals by 2.9% in the first quarter. Raymond James Trust N.A. now owns 5,705 shares of the company’s stock worth $229,000 after buying an additional 159 shares in the last quarter. 89.08% of the stock is currently owned by institutional investors and hedge funds.
Ionis Pharmaceuticals, Inc. (IONS) opened at 47.16 on Tuesday. The company’s 50-day moving average price is $52.29 and its 200 day moving average price is $47.02. Ionis Pharmaceuticals, Inc. has a 12 month low of $24.58 and a 12 month high of $60.01. The company has a market capitalization of $5.86 billion, a price-to-earnings ratio of 226.73 and a beta of 3.14.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.03. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same quarter last year, the firm posted ($0.47) earnings per share. The firm’s revenue was up 170.7% on a year-over-year basis. Analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.03) EPS for the current fiscal year.
A number of brokerages have weighed in on IONS. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday, July 26th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 target price (up previously from $59.56) on shares of Ionis Pharmaceuticals in a report on Tuesday, July 25th. Sanford C. Bernstein began coverage on Ionis Pharmaceuticals in a report on Thursday, July 27th. They issued a “market perform” rating and a $57.00 target price on the stock. Stifel Nicolaus reaffirmed a “hold” rating and issued a $42.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, July 10th. Finally, TheStreet raised Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $47.67.
In other Ionis Pharmaceuticals news, major shareholder Ionis Pharmaceuticals Inc purchased 3,125,000 shares of the business’s stock in a transaction on Wednesday, July 19th. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $25,000,000.00. Following the completion of the transaction, the insider now directly owns 28,884,540 shares in the company, valued at approximately $231,076,320. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Stanley T. Crooke sold 16,500 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $52.10, for a total transaction of $859,650.00. Following the sale, the chairman now owns 51,476 shares of the company’s stock, valued at $2,681,899.60. The disclosure for this sale can be found here. Insiders sold 54,379 shares of company stock valued at $2,946,052 over the last quarter. 1.86% of the stock is owned by company insiders.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).
Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.